Oxidative stress and chronic renal failure: Markers and management

Journal of Nephrology

Volumn 15, Issue 4, 2002, Pages 336-341

  Massy, Ziad A ^a   Nguyen Khoa, Thao ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Advanced oxidation protein products; Chronic renal failure; Dialysis; Oxidative stress; Uremia; Vitamin E

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED OXIDATION PROTEIN PRODUCT; ALPHA TOCOPHEROL; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTIOXIDANT; ASCORBIC ACID; BIOLOGICAL MARKER; FOLINIC ACID; GAMMA TOCOPHEROL; ISOPROSTANE; LEUKOTRIENE B4; LIPOXYGENASE; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; PROSTAGLANDIN F2; RETINOL; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DISEASE MARKER; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HEMODIALYSIS; HUMAN; OXIDATION; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; UREMIA; VITAMIN SUPPLEMENTATION;

ANTIOXIDANTS; BIOLOGICAL MARKERS; CLINICAL TRIALS; DINOPROST; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FREE RADICALS; HUMANS; KIDNEY FAILURE, CHRONIC; LEUKOTRIENE B4; MALE; MALONDIALDEHYDE; OXIDATIVE STRESS; PROGNOSIS; REACTIVE OXYGEN SPECIES; RENAL DIALYSIS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VITAMIN A;

EID: 0036659799     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Nguyen-Khoa T, Massy ZA, Witko-Sarsat V, Canteloup S, Kebede M, Lacour B, Drueke T, Descamps-Latscha B. Oxidized low-density lipoprotein induces macrophage respiratory burst via its protein moiety: A novel pathway in atherogenesis? Biochem Biophys Res Commun 1999; 263: 804-9.
2. Maggi E, Bellazzi R, Falaschi F, Frattoni A, Perani G, Finardi G, Gazo A, Nai M, Romanini D, Bellomo G. Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis? Kidney Int 1994; 45: 876-83.
3. Westhuyzen J, Saltissi D, Healy H. Oxidation of low density lipoprotein in hemodialysis patients: effect of dialysis and comparison with matched controls. Atherosclerosis 1997; 129: 199-205.
4. Nguyen-Khoa T, Massy ZA, Witko-Sarsat V, Thevenin M, Touam M, Lambrey G, Lacour B, Drüeke TB, Descamps-Latscha B. Critical evaluation of plasma and LDL oxidant trapping potential in hemodialysis patients. Kidney Int 1999; 56: 747-53.
5. Yeo HC, Helbock HJ, Chyu DW, Ames BN. Assay of malondialdehyde in biological fluids by gas chromatography-mass spectrometry. Anal Biochem 1994; 220: 391-6.
6. Gotoh M, Nagase S, Aoyagi K, Hirayama A, Takemura K, Ueda A, Tomida C, Kikuchi H, Koyama A. Thiobarbituric acid reactive substances are increased in the subcutaneous fat tissue of patients with end-stage renal disease. Nephrol Dial Transplant 1997; 12: 713-7.
7. Taccone-Gallucci M, Lubrano R, Belli A, Citti G, Morosetti M, Meloni C, Elli C, Mazzarella V, Tozzo C, Meschini L, Giardini O, Casciani CU. Lack of oxidative damage in serum polyunsaturated fatty acids before and after dialysis in chronic uremic patients. Int J Artif Organs 1989; 12: 515-8.
8. Pratico D, Lawson JA, Rokach J, FitzGerald GA. The isoprostanes in biology and medicine. Trends Endocrinol Metab 2001; 12: 243-7.
9. Handelman GJ, Walter MF, Adhikarla R, Gross J, Dallal GE, Levin NW, Blumberg JB. Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int 2001; 59: 1960-6.
10. Maggi E, Bellazzi R, Gazo A, Seccia M, Bellomo G. Autoantibodies against oxidatively-modified LDL in uremic patients undergoing dialysis. Kidney Int 1994; 46: 869-76.
11. Holvoet P, Donck J, Landeloos M, Brouwers E, Luijtens K, Arnout J, Lesaffre E, Vanrenterghem Y, Collen D. Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure. Thromb Haemost 1996; 76: 663-9.
12. Nguyen-Khoa T, Massy ZA, De Bandt JP, Kebede M, Salama L, Lambrey G, Witko-Sarsat V, Drueke TB, Lacour B, Thevenin M. Oxidative stress and haemodialysis: role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant 2001; 16: 335-40.
13. Miyata T, Sugiyama S, Saito A, Kurokawa K. Reactive carbonyl compounds related uremic toxicity ("carbonyl stress"). Kidney Int 2001; 78 (suppl): S25-31.
14. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Descamps-Latscha B. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49: 1304-13.
15. Massy ZA. Importance of homocysteine, lipoprotein (a) and non-classical cardiovascular risk factors (fibrinogen and advanced glycation end-products) for atherogenesis in uraemic patients. Nephrol Dial Transplant 2000; 5 (suppl 5): S81-91.
16. Tarng DC, Huang TP, Liu TY, Chen HW, Sung YJ, Wei YH. Effect of vitamin E-bonded membrane on the 8-hydroxy 2′-deoxyguanosine level in leukocyte DNA of hemodialysis patients. Kidney Int 2000; 58: 90-9.
17. Satoh M, Yamasaki Y, Nagake Y, Kasahara J, Hashimoto M, Nakanishi N, Makino H. Oxidative stress is reduced by the long-term use of vitamin E-coated dialysis filters. Kidney Int 2001; 59: 1943-50.
18. Ravanat JL, Cadet J. Reaction of singlet oxygen with 2′-deoxyguanosine and DNA. Isolation and characterization of the main oxidation products. Chem Res Toxicol 1995; 8: 379-88.
19. Bakaev V, Eferemov A, Tityaev I. Low levels of dehydroacorbic acid in uraemic serum and the partial correction of dehydroascorbic acid deficiency by hemodialysis. Nephrol Dial Transplant 1999; 14: 1472-4.
20. Davi G, Alessandrini P, Mezzetti A, Minotti G, Bucciarelli T, Costantini F, Cipollone F, Bon GB, Ciabattoni G, Patrono C. In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997; 17: 230-5.
21. Meagher EA, Barry OP, Lawson JA, Rokach J, FitzGerald GA. Effects of vitamin E on lipid peroxidation in healthy persons. JAMA 2001; 285: 1178-82.
22. Giardini O, Taccone-Gallucci M, Lubrano R, Ricciardi-Tenore G, Bandino D, Silvi I, Paradisi C, Mannarino O, Citti G, Elli M, Casciani CU. Effects of alpha-tocopherol administration on red blood cell membrane lipid peroxidation in hemodialysis patients. Clin Nephrol 1984; 21: 174-7.
23. Taccone-Gallucci M, Lubrano R, Del Principe D, Menichelli A, Giordani M, Citti G, Morosetti M, Meloni C, Mazzarella V, Meschini L, Tozzo C, Elli M, Giardini O, Casciani CU. Platelet lipid peroxidation in haemodialysis patients: effects of vitamin E supplementation. Nephrol Dial Transplant 1989; 4: 975-8.
24. Lubrano R, Taccone-Gallucci M, Piazza A, Morosetti M, Meloni C, Citti G, Mannarino O, Castello MA, Casciani CU. Vitamin E supplementation and oxidative status of peripheral blood mononuclear cells and lymphocyte subsets in hemodialysis patients. Nutrition 1992; 8: 94-7.
25. Yukawa S, Hibino A, Maeda T, Mimura K, Yukawa A, Maeda A, Kishino M, Sonobe M, Mune M, Yamada Y, Niside I. Effect of alpha-tocopherol on in vitro and in vivo metabolism of low-density lipoproteins in haemodialysis patients. Nephrol Dial Transplant 1995; 10 (suppl 3): S1-3.
26. Hassan MQ, Hussain SA, Zaki MA, Alsharif NZ, Stohs SJ. Protective effects of antioxidants against uraemia-induced lipid peroxidation and glutathione depletion in humans. Pharmacol Toxicol 1995; 77: 407-11.
27. Cristol JP, Bosc JY, Badiou S, Leblanc M, Lorrho R, Descomps B, Canaud B. Erythropoietin and oxidative stress in haemodialysis: beneficial effects of vitamin E supplementation. Nephrol Dial Transplant 1997; 12: 2312-7.
28. Islam KN, O'Byrne D, Devaraj S, Palmer B, Grundy SM, Jialal I. Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy. Atherosclerosis 2000; 150: 217-24.
29. Roob JM, Khoschsorur G, Tiran A, Horina JH, Holzer H, Winklhofer-Roob BM. Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 2000; 11: 539-49.
30. Maccarrone M, Meloni C, Manca- di-Villahermosa S, Cococcetta N, Casciani CU, Finazzi-Agro A, Taccone-Gallucci M. Vitamin E suppresses 5-lipoxygenase-mediated oxidative stress in peripheral blood mononuclear cells of hemodialysis patients regardless of administration route. Am J Kidney Dis 2001; 37: 964-9.
31. Antos M, Jeren-Strujic B, Raos V, Romic Z, Matanovic B. Evidence of antioxidant role of vitamin C in chronic hemodialysis patients. Clin Nephrol 1997; 14: 159-61.
32. Eiselt J, Racek J, Trefil L, Opatrny K, Jr. Effects of a vitamin E-modified dialysis membrane and vitamin C infusion on oxidative stress in hemodialysis patients. Artif Organs 2001; 25: 430-6.
33. Usberti M, Lima G, Arisi M, Bufano G, D'Avanzo L, Gazzotti RM. Effect of exogenous reduced glutathione on the survival of red blood cells in hemodialyzed patients. J Nephrol 1997; 10: 261-5.
34. De Cavanagh E, Ferder L, Carrasquedo F, Scrivo D, Wassermann A, Fraga C, Fraga C, Inserra F. Higher levels of antioxidant defenses in Enalapril-treated versus non-Enalapril-treated hemodialysis patients. Am J Kidney Dis 1999; 34: 445-55.
35. Nishikawa O, Mune M, Miyano M, Nishide T, Nishide I, Maeda A, Kimura K, Takahashi T, Kishino M, Tone Y, Otani H, Ogawa A, Maeda T, Yukawa S. Effect of simvastatin on the lipid profile of hemodialysis patients. Kidney Int 1999; 71 (suppl): S219-21.
36. Bayes B, Pastor MC, Bonal J, Junca J, Romero R. Homocysteine and lipid peroxidation in haemodialysis: role of folinic acid and vitamin E. Nephrol Dial Transplant 2001; 16: 2172-5.
37. Jadoul M, Ueda Y, Yasuda Y, Saito A, Robert A, Ishida N, Kurokawa K, Van Ypersele De Strihou C, Miyata T. Influence of hemodialysis membrane type on pentosidine plasma level, a marker of "carbonyl stress". Kidney Int 1999; 55: 2487-92.
38. Clermont G, Lecour S, Cabanne JF, Motte G, Guilland JC, Chevet D, Rochette L. Vitamin E-coated dialyzer reduces oxidative stress in hemodialysis patients. Free Radic Biol Med 2001; 31: 233-41.
39. Dhondt A, Vanholder R, Glorieux G, Waterloos MA, De Smet R, Lesaffer G, Lameire N. Vitamin E-bonded cellulose membrane and hemodialysis bioincompatibility: absence of an acute benefit on expression of leukocyte surface molecules. Am J Kidney Dis 2000; 36: 1140-6.
40. Wratten ML, Navino C, Tetta C, Verzetti G. Haemolipodialysis. Blood Purif 1999; 17: 127-33.
41. Annuk M, Zilmer M, Lind L, Linde T, Fellstrom B. Oxidative stress and endothelial function in chronic renal failure. J Am Soc Nephrol 2001; 12: 2747-52.
42. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899-911.
43. Bolton CH, Downs LG, Victory JG, Dwight JF, Tomson CR, Mackness MI, Pinkney JH. Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol Dial Transplant 2001; 16: 1189-97.
44. Boaz M, Matas Z, Biro A, Katzir Z, Green M, Fainaru M, Smetana S. Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis. Kidney Int 1999; 56: 1078-83.
45. Faggiotto A, Poli A, Catapano AL. Antioxidants and coronary artery disease. Curr Opin Lipidol 1998; 9: 541-9.
46. Neuzil J, Weber C, Kontush A. The role of vitamin E in atherogenesis: linking the chemical, biological and clinical aspects of the disease. Atherosclerosis 2001; 157: 257-83.
47. Mune M, Yukawa S, Kishino M, Otani H, Kimura K, Nishikawa O, Takahashi T, Kodama N, Saika Y, Yamada Y. Effect of vitamin E on lipid metabolism and atherosclerosis in ESRD patients. Kidney Int 1999; 71 (suppl): S126-9.
48. Miyazaki H, Matsuoka H, Itabe H, Usui M, Ueda S, Okuda S, Imaizumi T. Hemodialysis impairs endothelial function via oxidative stress: effects of vitamin E-coated dialyzer. Circulation 2000; 7; 101: 1002-6.
49. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M, Green MS. Secondary prevention with antioxidants of cardiovascular disease in end-stage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000 7; 356: 1213-8.
50. Landmesser U, Harrison DG. Oxidant stress as a marker for cardiovascular events: Ox marks the spot. Circulation 2001; 104: 2638-40.
51. Christen S, Woodall AA, Shigenaga MK, Southwell-Keely PT, Duncan MW, Ames BN. Gamma-tocopherol traps mutagenic electrophiles such as NO(X) and complements alpha-tocopherol: physiological implications. Proc Natl Acad Sci USA 1997; 94: 3217-22.
52. Handelman GJ, Machlin LJ, Fitch K, Weiter JJ, Dratz EA. Oral alpha-tocopherol supplements decrease plasma gamma-tocopherol levels in humans. J Nutr 1985; 115: 807-13.